These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 10955074)

  • 21. Hypersensitivity pneumonitis as a complication of intravesical BCG therapy for bladder cancer.
    Carrasco Hernández L; Castaño Núñez ÁL; Rodríguez Portal JA
    Arch Bronconeumol; 2016 Aug; 52(8):445-6. PubMed ID: 26920491
    [No Abstract]   [Full Text] [Related]  

  • 22. US case of the day. Granulomatous prostatitis resulting from BCG therapy.
    Rifkin MD; Tessler FN; Tublin ME; Ross JS
    Radiographics; 1998; 18(6):1605-7. PubMed ID: 9821203
    [No Abstract]   [Full Text] [Related]  

  • 23. BCGitis detected by (18)F-FDG PET/CT after treatment of bladder urothelial carcinoma.
    Jiménez Londoño GA; García Vicente AM; Ros Izquierdo J; Tello Galán MJ; González García B; Pena Pardo FJ; Palomar Muñoz A; Soriano Castrejón ÁM
    Rev Esp Med Nucl Imagen Mol; 2016; 35(2):141-2. PubMed ID: 26522000
    [No Abstract]   [Full Text] [Related]  

  • 24. [The influence over the long-term prognosis of BCG therapy and the surgical treatment in superficial bladder cancer treatment].
    Higashi S; Matsui Y; Takahashi T; Nishiyama H; Ito N; Yamamoto S; Kamoto T; Ogawa O
    Hinyokika Kiyo; 2005 Aug; 51(8):529-31. PubMed ID: 16164268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carcinoma of the bladder.
    Lamm DL
    Tex Med; 1985 Feb; 81(2):32-4. PubMed ID: 3983864
    [No Abstract]   [Full Text] [Related]  

  • 26. Conservative management of mucosal prostatic urethral involvement in patients with superficial transitional cell carcinoma of the bladder.
    Canda AE; Tuzel E; Mungan MU; Yorukoglu K; Kirkali Z
    Eur Urol; 2004 Apr; 45(4):465-9; discussion 469-70. PubMed ID: 15041110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Comparative study of treatments of bladder carcinoma: TUR, thiotepa or BCG].
    Rodrigues Netto Júnior N; Caserta Lemos G
    Arch Esp Urol; 1981; 34(5):369-74. PubMed ID: 6800309
    [No Abstract]   [Full Text] [Related]  

  • 28. Miliary tuberculosis: a complication of intravesical BCG treatment.
    Foster DR
    Australas Radiol; 1998 May; 42(2):167-8. PubMed ID: 9599839
    [No Abstract]   [Full Text] [Related]  

  • 29. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Abdominal and retroperitoneal abscesses in a patient with bladder carcinoma receiving BCG therapy].
    Fernández JM; Cartón JA; Rodríguez A; Asensi V
    Enferm Infecc Microbiol Clin; 2009 Oct; 27(8):485-6. PubMed ID: 19406520
    [No Abstract]   [Full Text] [Related]  

  • 31. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG).
    Saint F; Le Frere Belda MA; Quintela R; Hoznek A; Patard JJ; Bellot J; Popov Z; Zafrani ES; Abbou CC; Chopin DK; de Medina SG
    Eur Urol; 2004 Apr; 45(4):475-82. PubMed ID: 15041112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The safety and efficacy of different doses of bacillus Calmette Guérin in superficial bladder transitional cell carcinoma.
    Agrawal MS; Agrawal M; Bansal S; Agarwal M; Lavania P; Goyal J
    Urology; 2007 Dec; 70(6):1075-8. PubMed ID: 18158020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Innovative approaches for superficial bladder tumors.
    Oosterlinck W; Abi-Aad A
    Acta Urol Belg; 1996 May; 64(2):31-2. PubMed ID: 8701806
    [No Abstract]   [Full Text] [Related]  

  • 34. Difficult decisions in urologic oncology: management of high-grade T1 transitional cell carcinoma of the bladder.
    Soloway MS; Lee CT; Steinberg GD; Ghandi AA; Jewett MA
    Urol Oncol; 2007; 25(4):338-40. PubMed ID: 17628304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bladder cancer and BCG response prediction: what we must know?
    Cai T; Malossini G
    Cancer; 2011 Feb; 117(4):872; author reply 872-3. PubMed ID: 20922798
    [No Abstract]   [Full Text] [Related]  

  • 36. Primary neuroendocrine carcinoma of the urethra.
    Parekh DJ; Jung C; Roberts R; Shappell S; Smith JA
    Urology; 2002 Dec; 60(6):1111. PubMed ID: 12475683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.
    Demkow T; Alter A; Wiechno P
    Urol Int; 2008; 80(1):74-9. PubMed ID: 18204238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Editorial comment on: celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma.
    Brandau S
    Eur Urol; 2008 Sep; 54(3):629-30. PubMed ID: 18222602
    [No Abstract]   [Full Text] [Related]  

  • 39. Predicting bacillus Calmette-Guerin immunotherapy effectiveness.
    Griffith TS
    J Urol; 2007 Dec; 178(6):2247-8. PubMed ID: 17936825
    [No Abstract]   [Full Text] [Related]  

  • 40. [Radical cystectomy for superficial tumors in the BCG era].
    Huguet Pérez J; Palou J; Millán Rodríguez F; Villavicencio Mavrich H; Rodríguez JV
    Arch Esp Urol; 2002; 55(1):50-6. PubMed ID: 11957752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.